A phase I study of TAS-109 given by 14-day continuous central intravenous infusion in patients with advanced solid tumors (TAS109-0401)

Trial Profile

A phase I study of TAS-109 given by 14-day continuous central intravenous infusion in patients with advanced solid tumors (TAS109-0401)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2009

At a glance

  • Drugs TAS 109 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
    • 02 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top